Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes

Journal of Urology

Volumn 159, Issue 6, 1998, Pages 2164-2171

  Ballard, Stephen A ^a   Gingell, Clive J ^b   Tang, Kim ^b   Turner, Leigh A ^b   Price, Mary E ^b   Naylor, Alasdair M ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b NONE

Author keywords

Guanylate cyclase; Impotence; Nitric oxide; Penile erection; Phosphodiesterase inhibitors

Indexed keywords

CYCLIC GMP PHOSPHODIESTERASE INHIBITOR; NITRIC OXIDE; PHENYLEPHRINE; SILDENAFIL; UNCLASSIFIED DRUG; ZAPRINAST;

ADULT; AGED; ARTICLE; CATTLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG MECHANISM; DRUG POTENCY; ELECTROSTIMULATION; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROLYSIS; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

EID: 0032445219     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63299-3     Document Type: Article

References (28)

1. Lue, T. F.: Hemodynamics of erection in the monkey. J. Urol., 130: 1237, 1983.
2. Andersson, K-E. and Wagner, G.: Physiology of penile erection. Physiol. Rev., 75: 191, 1995.
3. Burnett, A. L. Lowenstein, C. J., Bredt D. S., Chang, T. S. K. and Snyder, S. H.: Nitric oxide: a physiologic mediator of penile erection. Science, 257: 401, 1992.
4. Trigo-Rocha, F., Hsu, G. L., Donatucci, C. F. and Lue, T. F.: The role of cyclic adenosine monophosphate, cyclic guanosine monophosphate, endothelium and nonadrenergic, noncholinergic neurotransmission in canine penile erection. J. Urol., 149: 872, 1993.
5. Burnett, A. L.: Role of nitric oxide in the physiology of erection. Biol. Reprod., 52: 485, 1995.
6. Beavo, J. A.: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev., 75: 725, 1995.
7. Bush, P. A., Aronson, W. J., Georgette, M. B., Rajfer, J. and Ignarro, L. J.: Nitric Oxide is a potent relaxant of human and rabbit corpus cavernosum. J. Urol., 147: 1650, 1992.
8. Rajfer, J., Aronson, W. J., Bush, P. A., Dorey, F. J. and Ignarro, L. J.: Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N. Engl. J. Med., 326: 90, 1992.
9. Trigo-Rocha, F., Aronson, W. J., Hohenfellner, M., Ignarro, L. J., Rajfer, J. and Lue, T. F.,.: Nitric oxide and cGMP: mediators of pelvic nerve-stimulated erection in dogs. Am. J. Physiol., 264 (Heart Circ: Physiol. 33): H419, 1993.
10. Trigo-Rocha, F., Hsu, G-L., Donatucci, C. F. Martinez-Pineiro, L., Lue, T. F. and Tanagho, E. A.: Intracellular mechanism of penile erection in monkeys. Neurourol. Urodynam., 13: 71, 1994.
11. Beavo, J. A., Conti, M. and Heaslip, R. J.: Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol., 46: 399, 1994.
12. Boolell, M., Allen, M. J., Ballard, S. A., Gepi-Attee, S., Muirhead, G. J., Naylor, A. M., Osterloh, I. H. and Gingell, J. C.: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Imp. Res., 8: 47, 1996.
13. Jeremy, J. Y., Ballard, S. A., Naylor, A. M., Miller, M. A. W. and Angelini, G. D.: Effects of sildenafil, a type 5 cyclic GMP phosphodiesterase inhibitor on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br. J. Urol., 79: 958, 1997.
14. Lue, T. F. and the Sildenafil Study Group.: A study of sildenafil (VIAGRA™), a new oral agent for the treatment of male erectile dysfunction. J. Urol., 157(suppl.): 181, 1997.
15. Boolell, M., Gepi-Attee, S., Gingell, J. C. and Allen, M. J.: Sildenafil, a novel oral therapy for male erectile dysfunction. Br. J. Urol., 78: 257, 1996.
16. Moro, M. A., Russell, R. J., Cellek, S., Lizasoin, I., Su, Y., Darley-Usmar, V. M., Radomski, M. W. and Moncada, S.: cGMP mediates the vascular and platelet actions of nitric oxide: Confirmation using an inhibitor of soluble guanylate cyclase. Proc. Natl. Acad. Sci., 93: 1480, 1996.
17. Beavo, J. A. and Reifsnyder, D. H.: Primary sequence of cyclic nucleotide phosphodiesterase enzymes and the design of selective inhibitors. Trends Pharmacol. Sci., 11: 150, 1990.
18. Thompson, W. J. and Appleman, M. M.: Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry, 10: 311, 1971.
19. De Lean, A., Munson, A. and Rodbard, D.: Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol., 235: E97, 1978.
20. Pickard, R. S., Powell, P. H. and Zar, M. A.: The effect of inhibitors of nitric oxide biosynthesis and cyclic GMP formation on nerve-evoked relaxation of human cavernosal smooth muscle. Br. J. Pharmacol., 104: 755, 1991.
21. Knispel, H. H., Goessl, C. and Beckmann, R.: Nitric oxide mediates relaxation in rabbit and human corpus cavernosum smooth muscle. Urol. Res., 20: 253, 1992.
22. Stieff, C. G.: Phosphodiesterase isozymes of the human cavernous tissue and its functional significance. Akt. Urol., 26: 22, 1995.
23. Gillespie, P. G. and Beavo, J. A.: Inhibition and stimulation of photoreceptor by dipyridamole and M&B 22,948. Mol. Pharm., 36: 773, 1989.
24. Hurwitz, R. L., Bunt-Milam, A. H., Chang, M. L. and Beavo, J. A.: cGMP phosphodiesterase in rod and cone outer segments of the retina. J. Biol. Chem., 260: 568, 1985.
25. Burns, F., Rodger, I. W. and Pyne N. J.: The catalytic subunit of protein kinase A triggers activation of the type V cyclic GMP specific phosphodiesterase from guinea pig lung. Biochem. J., 283: 487, 1992.
26. Thomas, M. K. Frances, S. H. and Corbin, J. D.: Characterization of purified bovine lung cGMP-binding cGMP phosphodiesterase. J. Biol. Chem., 265: 14964, 1990.
27. Terrett, N, K., Bell, A. S., Brown, D. and Ellis, P.: Sildenafil (VIAGRA™), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg. Med. Chem. Lett., 6: 1819, 1996.
28. Bush, K.: Screening and characterization of enzyme inhibitors as drug candidates. Drug Met. Rev., 14: 639, 1983.